Serious eye disorders. Consultation on draft quality standard, joint submisison from The Royal College of Ophthalmologists with The College of Optometrists and Vision UK

2 October 2018

This quality standard will cover the diagnosis and management of serious eye conditions in adults including cataracts, glaucoma and macular degeneration. It will also cover preventing sight loss in adults. This quality standard will replace the existing NICE quality standard for Glaucoma in adults (QS7). The topic was identified for update following the annual review of quality standards in 2017.

Read more Serious eye disorders. Consultation on draft quality standard, joint submisison from The Royal College of Ophthalmologists with The College of Optometrists and Vision UK
NICE QS Chronic Disease Joint Response With RCOphth COO And Vision UK V1.4
NICE QS Chronic Disease Joint Response With RCOphth COO And Vision UK V1.4
Download pdf 0.7 MB

NICE impact falls and fragility fractures published

23 August 2018
Source: NICE

Each year, almost a third of over 65s fall at least once and there are an estimated 500,000 fragility fractures. This report considers how NICE’s evidence-based guidance might contribute to improvements in the prevention and management of falls and fragility fractures.   This report highlights progress made by the healthcare system in implementing NICE guidance. NICE recognise that change can

Read more NICE impact falls and fragility fractures published
NICE-Impact-falls-and-fragility-fractures
NICE-Impact-falls-and-fragility-fractures
Download pdf 1.5 MB

NICE publish: Intermediate care including reablement quality standard

21 August 2018
Source: NICE

Quality standard [QS173] Published date: August 2018 What the quality statement means for different audiences: Service providers (such as hospitals, community providers, local authorities, care homes, home care agencies and not-for-profit social enterprises) ensure that staff carrying out assessments for intermediate care have the knowledge and materials to provide information and have a discussion with the person (and their family

Read more NICE publish: Intermediate care including reablement quality standard

NICE: Dementia: assessment, management and support for people living with dementia and their carers

3 July 2018
Source: NICE

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia. NICE has also produced a guideline on mid-life approaches to delay or prevent the onset of dementia. Recommendations This guideline includes recommendations on: involving people living with dementia in decisions

Read more NICE: Dementia: assessment, management and support for people living with dementia and their carers

Vision UK response to the NICE Consultation: Dementia: assessment, management and support for people living with dementia and their carers

12 February 2018
Source: Vision UK Dementia & Sight Loss Committee

Vision UK response to the NICE Consultation: Dementia: assessment, management and support for people living with dementia and their carers attached below:  

Read more Vision UK response to the NICE Consultation: Dementia: assessment, management and support for people living with dementia and their carers
NICE Comments-form-Dementia Vision UK 02.18
NICE Comments-form-Dementia Vision UK 02.18
Download doc 87 KB

Macular Society: Eye patients to be treated earlier

24 January 2018
Source: The Macular Society

The National Institute for Health and Care Excellence (NICE) has cleared the way for eye patients to be treated on the NHS before they have to stop driving. National sight loss charity the Macular Society has welcomed the recommendation, which has been included in the new Clinical Guideline on the diagnosis and management of age-related macular degeneration (AMD). Currently, AMD

Read more Macular Society: Eye patients to be treated earlier

NICE guideline on age-related macular degeneration published

23 January 2018
Source: NICE

23/01/18 This final guideline has now been published on the NICE website. You can also find the supporting evidence, as well as all the stakeholder comments that they received during consultation and the responses to these comments. The comments were invaluable in helping them to develop and refine the guideline. They have also produced an equality impact assessment to support the

Read more NICE guideline on age-related macular degeneration published

NICE Committee member recruitment – Workplace health: long term sickness and incapacity to work update committee

4 January 2018
Source: NICE

This is a quick reminder that the deadline for applying to join NICE’s Workplace health: long  term sickness and incapacity to work update committee as a topic expert or a lay member, is 5pm 9th January. Further details of the topic expert roles can be found on the NICE website Further details of the lay member roles can be found

Read more NICE Committee member recruitment – Workplace health: long term sickness and incapacity to work update committee

Support people to make decisions if they have capacity but find it difficult, NICE says

3 January 2018
Source: NICE

Health and social care professionals should support people to make decisions who find it difficult, NICE says in new draft guidance.   They should support people even if they make a decision that they may disagree with. Making an ‘unwise’ or ‘risky’ choice does not mean that a person lacks capacity and decisions need to be made on their behalf, the

Read more Support people to make decisions if they have capacity but find it difficult, NICE says

FDA approves Luxturna to treat patients with inherited retinal disease

21 December 2017
Source: FIght for Sight

The US Food and Drug Administration (FDA) has this week approved the first ever gene therapy treatment, Luxturna (Voretigene Neparvovec), for inherited retinal diseases (IRD).The gene therapy drug will be used as a treatment for patients with vision loss caused by RPE65 gene mutations. Mutations in the RPE65 gene are associated with two main types of IRDs – retinitis pigmentosa

Read more FDA approves Luxturna to treat patients with inherited retinal disease